Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130.
Hashimoto. Yuichi Y; Kurita. Megumi M; Aiso. Sadakazu S; Nishimoto. Ikuo I; Matsuoka. Masaaki M
Key Findings
- Humanin stops neuron death caused by Alzheimer‑related stressors in cell culture
- The protective effect requires the gp130 receptor subunit and the CNTFR and WSX‑1 subunits
- Humanin triggers these three proteins to stick together, forming a signaling complex that activates STAT3
Practical Outcomes
- For biohackers, this research suggests humanin could be a promising neuro‑protective supplement for brain health and longevity, but it’s still early‑stage and limited to lab cells. No human dosing or safety data are provided, so any use would be experimental and should be approached cautiously, possibly combined with other strategies that support STAT3 signaling.
Summary
Humanin is a tiny protein that can protect brain cells from dying, and it does this by hooking onto a specific group of cell‑surface receptors (CNTFR, WSX‑1 and gp130) that then turn on protective signaling inside the cell. The study shows exactly which receptors are needed for this effect, confirming that humanin works through a cytokine‑type pathway rather than some unknown mechanism.
Abstract
Humanin (HN) inhibits neuronal death induced by various Alzheimer's disease (AD)-related insults via an unknown receptor on cell membranes. Our earlier study indicated that the activation of STAT3 was essential for HN-induced neuroprotection, suggesting that the HN receptor may belong to the cytokine receptor family. In this study, a series of loss-of-function tests indicated that gp130, the common subunit of receptors belonging to the IL-6 receptor family, was essential for HN-induced neuroprotection. Overexpression of ciliary neurotrophic factor receptor alpha (CNTFR) and/or the IL-27 receptor subunit, WSX-1, but not that of any other tested gp130-related receptor subunit, up-regulated HN binding to neuronal cells, whereas siRNA-mediated knockdown of endogenous CNTFR and/or WSX-1 reduced it. These results suggest that both CNTFR and WSX-1 may be also involved in HN binding to cells. Consistent with these results, loss-of-functions of CNTFR or WSX-1 in neuronal cells nullified their responsiveness to HN-mediated protection. In vitro-reconstituted binding assays showed that HN, but not the other control peptide, induced the hetero-oligomerization of CNTFR, WSX-1, and gp130. Together, these results indicate that HN protects neurons by binding to a complex or complexes involving CNTFR/WSX-1/gp130.
Study Information
pubmed
2009
2009-04-22T00:00:00.000Z
10.1091/mbc.e09-02-0168